TY - JOUR
T1 - Identification of traumatic acid as a potential plasma biomarker for sarcopenia using a metabolomics-based approach
AU - Tsai, Jaw Shiun
AU - Wang, San Yuan
AU - Chang, Chin Hao
AU - Chen, Chin Ying
AU - Wen, Chiung Jung
AU - Chen, Guan Yuan
AU - Kuo, Ching Hua
AU - Tseng, Y. Jane
AU - Chen, Ching Yu
N1 - Funding Information:
This study was supported by grants (NSC 98‐2314‐B‐002‐118‐MY2, MOST 107‐2314‐B‐002‐273, MOST 108‐2314‐B‐002‐106, and MOST 109‐2314‐B‐002‐165‐MY3 to Jaw‐Shiun Tsai; PH‐098‐PP‐48 to Ching‐Yu Chen) from the National Science Council and the National Health Research Institutes, Taiwan. The financial sponsors played no role in any aspect of the study.
Publisher Copyright:
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
PY - 2022/2
Y1 - 2022/2
N2 - Background: The pathogenesis of sarcopenia is complex and has not been well explored. Identifying biomarkers is a promising strategy for exploring the mechanism of sarcopenia. This study aimed to identify potential biomarkers of sarcopenia through a metabolomic analysis of plasma metabolites in elderly subjects (≥65 years of age) vs. younger adults (<65 years of age). Methods: Of the 168 candidates in the Comprehensive Geriatric Assessment and Frailty Study of Elderly Outpatients, 24 elderly subjects (≥65 years of age) with sarcopenia were age and sex matched with 24 elderly subjects without sarcopenia. In addition, 24 younger adults were recruited for comparison. Muscle strength, gait speed, and metabolic and inflammatory parameters, including plasma tumour necrosis factor-α, C-reactive protein, irisin, and growth differentiation factor 15 (GDF-15) levels were assessed. Metabolomic analysis was carried out using the plasma metabolites. Results: Seventy-two participants were enrolled, including 10 (41.6%) men and 14 (58.3%) women in both groups of elderly subjects. The median ages of elderly subjects with and without sarcopenia were 82 (range: 67–88) and 81.5 (range: 67–87) years, respectively. Among the 242 plasma metabolic peaks analysed among these three groups, traumatic acid was considered as a sarcopenia-related metabolite. The plasma traumatic acid signal intensity level was significantly higher in elderly subjects with sarcopenia than in elderly subjects without sarcopenia [591.5 (inter-quartile range, IQR: 491.5–664.5) vs. 430.0 (IQR: 261.0–599.5), P = 0.0063]. The plasma concentrations of traumatic acid were 15.8 (IQR: 11.5–21.7), 21.1 (IQR: 16.0–25.8), and 24.3 (IQR: 18.0–29.5) ppb in younger adults [age range: 23–37 years, 12 (50%) men], elderly subjects without sarcopenia, and elderly subjects with sarcopenia, respectively, thereby depicting an increasing tendency (P for trend = 0.034). This pattern was similar to that of GDF-15, a recognized sarcopenia-related factor. Plasma traumatic acid concentrations were also positively correlated with the presence of hypertension (r = 0.25, P = 0.034), glucose AC (r = 0.34, P = 0.0035), creatinine (r = 0.40, P = 0.0006), and GDF-15 levels (r = 0.25, P = 0.0376), but negatively correlated with the Modification of Diet in Renal Disease-simplify-glomerular filtration rate (r = −0.50, P < 0.0001). Similarly, plasma GDF-15 concentrations were associated with these factors. Conclusions: Traumatic acid might represent a potential plasma biomarker of sarcopenia. However, further studies are needed to validate the results and investigate the underlying mechanisms.
AB - Background: The pathogenesis of sarcopenia is complex and has not been well explored. Identifying biomarkers is a promising strategy for exploring the mechanism of sarcopenia. This study aimed to identify potential biomarkers of sarcopenia through a metabolomic analysis of plasma metabolites in elderly subjects (≥65 years of age) vs. younger adults (<65 years of age). Methods: Of the 168 candidates in the Comprehensive Geriatric Assessment and Frailty Study of Elderly Outpatients, 24 elderly subjects (≥65 years of age) with sarcopenia were age and sex matched with 24 elderly subjects without sarcopenia. In addition, 24 younger adults were recruited for comparison. Muscle strength, gait speed, and metabolic and inflammatory parameters, including plasma tumour necrosis factor-α, C-reactive protein, irisin, and growth differentiation factor 15 (GDF-15) levels were assessed. Metabolomic analysis was carried out using the plasma metabolites. Results: Seventy-two participants were enrolled, including 10 (41.6%) men and 14 (58.3%) women in both groups of elderly subjects. The median ages of elderly subjects with and without sarcopenia were 82 (range: 67–88) and 81.5 (range: 67–87) years, respectively. Among the 242 plasma metabolic peaks analysed among these three groups, traumatic acid was considered as a sarcopenia-related metabolite. The plasma traumatic acid signal intensity level was significantly higher in elderly subjects with sarcopenia than in elderly subjects without sarcopenia [591.5 (inter-quartile range, IQR: 491.5–664.5) vs. 430.0 (IQR: 261.0–599.5), P = 0.0063]. The plasma concentrations of traumatic acid were 15.8 (IQR: 11.5–21.7), 21.1 (IQR: 16.0–25.8), and 24.3 (IQR: 18.0–29.5) ppb in younger adults [age range: 23–37 years, 12 (50%) men], elderly subjects without sarcopenia, and elderly subjects with sarcopenia, respectively, thereby depicting an increasing tendency (P for trend = 0.034). This pattern was similar to that of GDF-15, a recognized sarcopenia-related factor. Plasma traumatic acid concentrations were also positively correlated with the presence of hypertension (r = 0.25, P = 0.034), glucose AC (r = 0.34, P = 0.0035), creatinine (r = 0.40, P = 0.0006), and GDF-15 levels (r = 0.25, P = 0.0376), but negatively correlated with the Modification of Diet in Renal Disease-simplify-glomerular filtration rate (r = −0.50, P < 0.0001). Similarly, plasma GDF-15 concentrations were associated with these factors. Conclusions: Traumatic acid might represent a potential plasma biomarker of sarcopenia. However, further studies are needed to validate the results and investigate the underlying mechanisms.
KW - Elderly
KW - Metabolomics
KW - Sarcopenia
KW - Traumatic acid
UR - http://www.scopus.com/inward/record.url?scp=85121597885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121597885&partnerID=8YFLogxK
U2 - 10.1002/jcsm.12895
DO - 10.1002/jcsm.12895
M3 - Article
AN - SCOPUS:85121597885
SN - 2190-5991
VL - 13
SP - 276
EP - 286
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
IS - 1
ER -